Want to see JP:2160 full AI Analyst Report?
2160 Stock Chart & Stats
¥3370.00
¥50.00(1.64%)
At close: 4:00 PM EST
¥3370.00
¥50.00(1.64%)
Day’s Range― - ―
52-Week Range¥2,112.00 - ¥3,740.00
Previous CloseN/A
Volume492.20K
Average Volume (3M)1.12M
Market Cap
¥213.97B
Enterprise Value¥172.97K
Total Cash (Recent Filing)¥17.16B
Total Debt (Recent Filing)¥5.07B
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Nov 16, 2026EPS Estimate
27.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-102.58
Shares Outstanding65,850,494
10 Day Avg. Volume1,022,940
30 Day Avg. Volume1,118,126
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.52
Price to Sales (P/S)4.71
P/FCF Ratio-46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥3,800.00Price Target Upside12.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)15.29
Revenue Forecast (FY)¥40.18B
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsA gross margin near 75% indicates the company retains substantial value from its revenue before operating costs. This provides a durable economic foundation and, if revenue stabilizes, leaves meaningful scope for improved operating leverage and future profitability.
Manageable LeverageLow debt relative to equity and a sizable equity base reduce balance-sheet pressure compared with a highly leveraged structure. This gives GNI Group more flexibility to manage periods of weak profitability and preserve strategic options over the coming quarters.
Established Revenue BaseThe company has demonstrated the ability to expand revenue across multiple periods, including strong growth in 2022–2023 and modest growth in 2025. That established revenue base supports continued commercialization efforts even though the latest momentum has weakened.
Bears Say
Renewed Losses And Earnings VolatilityThe return to sizable net and operating losses after profitability in 2023 shows that revenue is not converting consistently into earnings. This volatility weakens the durability of the business model and makes future capital allocation and performance more difficult to assess.
Persistent Cash BurnNegative operating and free cash flow indicate that current operations are consuming cash rather than funding the business internally. Continued cash burn can increase reliance on external funding and constrain investment capacity while profitability remains weak.
Deteriorating Revenue MomentumThe sharp deterioration in trailing revenue momentum raises concern that demand expansion has become less consistent than in earlier growth periods. Slower top-line progression can limit operating leverage and make it harder to absorb the company’s fixed operating costs.
GNI Group News
2160 FAQ
What was GNI Group Ltd.’s price range in the past 12 months?
GNI Group Ltd. lowest stock price was ¥2112.00 and its highest was ¥3740.00 in the past 12 months.
What is GNI Group Ltd.’s market cap?
GNI Group Ltd.’s market cap is ¥213.97B.
When is GNI Group Ltd.’s upcoming earnings report date?
GNI Group Ltd.’s upcoming earnings report date is Nov 16, 2026 which is in 53 days.
How were GNI Group Ltd.’s earnings last quarter?
GNI Group Ltd. released its earnings results on Aug 14, 2026. The company reported ¥2.54 earnings per share for the quarter, beating the consensus estimate of -¥61.64 by ¥64.18.
Is GNI Group Ltd. overvalued?
According to Wall Street analysts GNI Group Ltd.’s price is currently Undervalued.
Does GNI Group Ltd. pay dividends?
GNI Group Ltd. does not currently pay dividends.
What is GNI Group Ltd.’s EPS estimate?
GNI Group Ltd.’s EPS estimate is 27.3.
How many shares outstanding does GNI Group Ltd. have?
GNI Group Ltd. has 65,850,494 shares outstanding.
What happened to GNI Group Ltd.’s price movement after its last earnings report?
GNI Group Ltd. reported an EPS of ¥2.54 in its last earnings report, beating expectations of -¥61.64. Following the earnings report the stock price went up 1.312%.
Which hedge fund is a major shareholder of GNI Group Ltd.?
Currently, no hedge funds are holding shares in JP:2160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GNI Group Ltd.
GNI Group Ltd. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of both modern pharmaceuticals and traditional Chinese medicines. The company's lead product, Etuary, is currently available for the treatment of idiopathic pulmonary fibrosis. Beyond this, Etuary is undergoing further clinical evaluation: it is in Phase III trials for connective tissue disease-associated interstitial lung disease, and in Phase II along with a pre-Phase III pilot study for radiation pneumonitis. Investigations are also underway for its application in diabetic nephropathy. GNI Group Ltd.'s pipeline additionally features F351, which is in Phase II development for liver fibrosis; F573, an early-stage compound in pre-clinical testing for acute-on-chronic liver failure; and Tamibarotene, intended for the treatment of acute promyelocytic leukemia. Established in 2001, the company's headquarters are located in Tokyo, Japan.
2160 Stock 12 Month Forecast
Average Price Target
¥3,800.00
▲(12.76% Upside)